Fundoplication denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for fundoplication are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Fundoplication as "Duplicate Therapy" — and Why That Is Often Wrong

Fundoplication is a surgical procedure — typically a Nissen or partial fundoplication — used to treat gastroesophageal reflux disease (GERD) that has not been adequately controlled by medical management. A "duplicate therapy" denial from BCBS usually means the insurer's system flagged an overlap with another active treatment, most often ongoing proton pump inhibitor (PPI) therapy or a recent endoscopic procedure. However, surgery and ongoing medication are not truly duplicative — they address the structural cause of reflux rather than suppressing symptoms pharmacologically. This distinction is the core of a successful appeal.

## Why This Denial Is Frequently Overturned

Fundoplication is not a substitute for medication; it is a different modality addressing a different mechanism. When a patient continues on PPIs while awaiting surgery, or when both a diagnostic endoscopy and a surgical referral are active, BCBS's claims system can incorrectly categorize them as duplicating each other. The appeal should clearly establish that the procedures serve distinct clinical purposes and that the surgical approach is warranted because medical therapy has been inadequate or is not a long-term solution for your clinical situation.

## Federal Appeal Framework

• Internal appeal — File within the timeframe on your Explanation of Benefits (commonly 180 days). Under ERISA §503, request the specific criteria and the clinical policy BCBS used to classify the procedures as duplicative.
• ACA §2719 external review — After an adverse internal decision, you may request an Independent Review Organization review. Confirm the exact deadline on your denial letter; the standard window is approximately four months.
• Expedited review — If delay would seriously jeopardize your health — for example, if uncontrolled reflux is causing progressive esophageal injury — request expedited handling.

## Documentation to Gather

• Gastroenterologist or surgeon letter — A signed explanation of why fundoplication is medically necessary and how it differs clinically from ongoing pharmacologic therapy or prior endoscopic procedures.
• Treatment history — Dates, medications, doses (as described in chart notes), durations, and outcomes of prior GERD management, including any endoscopic findings.
• Diagnostic workup — Results of relevant studies (pH monitoring, manometry, endoscopy reports) that establish the clinical basis for surgical intervention, referenced by the treating physician.
• Distinction of modalities — A brief written explanation from the surgeon or gastroenterologist clarifying that medical therapy and surgical repair are not duplicative but sequential and mechanistically different.

## Criteria-Mapping Structure

| BCBS Policy Requirement | Chart Evidence | |---|---| | Confirmation that procedures are not duplicative | Surgeon/gastroenterologist letter explaining distinct mechanisms | | Medical necessity of surgical approach | Diagnostic study results + treatment failure history | | Appropriate diagnosis confirmed | ICD-10 code + specialist note | | Each additional policy criterion | Specific date-stamped chart reference |